Navigation Links
Additional Data From Satraplatin SPARC Phase 3 Trial Presented at,European Association of Urology Congress

plied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either GPC Biotech or Pharmion. Forward-looking statements speak only as of the date on which they are made and neither GPC Biotech nor Pharmion undertakes any obligation to update these forward-looking statements, even if new information becomes available in the future.

The scientific information discussed in this press release related to satraplatin is investigative. Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

CONTACT: Breanna Burkart, or Anna Sussman, Directors, Investor Relationsand Corporate Communications, both of Pharmion Corporation,+1-720-564-9150; or Martin Braendle, Director,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
Post Your Comments:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) ... Stars Outlook 2015" report to their offering. ... sought after with fresh vigor as new targets , ... poised to bring a paradigm change in the way ... Stem cell therapy/Regenerative Medicine space. The number ...
(Date:3/5/2015)... , March 5, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, announced today that ... top rehabilitation hospitals for spinal cord injury and brain ... trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured ... injury (SCI). The Phase 1/2a trial ...
(Date:3/5/2015)... , March 5, 2015 ... Medical Ltd., Tokyo, Japan , is ... compact, portable Ultrasound Bone Densitometry System at the European ... see and test EggQus at the Hitachi Medical Systems ... http://photos.prnewswire.com/prnh/20150305/732754-a ) ,      (Photo: ...
Breaking Medicine Technology:Global Pharma Rising Stars Outlook 2015 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Initiates Patient Enrollment for Phase 1/2a Clinical Trial of AST-OPC1 in Newly Injured People with Complete Cervical Spinal Cord Injury 4Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 2Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 3
... Limited (ASX: SPL, OTCQX: SPHRY) today announced successful results ... efficacy of VivaGel(R) for the treatment of bacterial vaginosis ... VivaGel(R) meets primary endpoint, demonstrating significant efficacy for ... shortcomings of existing therapies Trial results support new ...
... AMGN ), today announced results of voting at ... Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding ... director nominees David Baltimore, Frank J. Biondi, Jr., Francois de ... Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, USN ...
Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Amgen Announces Voting Results Of Annual Meeting of Stockholders 2Amgen Announces Voting Results Of Annual Meeting of Stockholders 3Amgen Announces Voting Results Of Annual Meeting of Stockholders 4
(Date:3/5/2015)... Altec Products, Inc., a leader in enterprise ... in the Houston, TX and Charlotte, NC conferences of ... unite Sage enterprise resource planning (ERP) software users with ... real-world business challenges. , The Houston, TX event ... Area on March 10th. The Charlotte, NC conference will ...
(Date:3/5/2015)... 05, 2015 March 5, 2015 – ... next week (March 8-14, 2015), children’s hospitals around the ... in making hospital stays as safe as possible for ... hospitals—Children’s Hospitals’ Solutions for Patient Safety (SPS) and the ... families to follow when visiting the hospital with their ...
(Date:3/5/2015)... GA (PRWEB) March 05, 2015 ... and relationship-marketing firm, honored finalists and winners Thursday ... Executive Forum and Awards Gala at the Westin ... chief security officer for EarthLink, was selected as ... winner for the ISE® Southeast Region. Pete is ...
(Date:3/5/2015)... The MTC 5-day Fundamental Implantology Course has been ... variety of dental disciplines, to offer implant placement treatment ... onset we wanted this course to be a truly ... excellence of the lecturers and the sheer energy and ... satisfied our aims." , Unlike large-scale training operations, ...
(Date:3/5/2015)... Grants Pass, OR (PRWEB) March 05, 2015 ... dehydrated and increasing the amount of water one drinks ... individuals. Those were the conclusions of fresh water advocate ... recent interview on the Sharon Kleyne Hour™ Powers of ... of Podiatric Medicine (DPM) specializing in podiatry, orthotics and ...
Breaking Medicine News(10 mins):Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 2Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 2Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 4Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 3
... http://www.westaim.com , CALGARY, Nov. 7 /PRNewswire-FirstCall/ - The ... on Tuesday, November 13, 2007 regarding the,Company,s 2007 third ... wire services, a news release,and financial statements will be ... call live on the Internet, please go to ...
... 7 Rapid Pathogen Screening Inc.,(RPS) -- a ... -- announced today that the American Medical Association ... that will cover the,RPS Adeno Detector(TM), effective January ... "Infectious agent antigen detection by immunoassay with direct ...
... The following is a,written statement by Kevin ... Force on Intellectual Property, at the Senate Judiciary,Committee ... Chairman Leahy, Ranking Member Specter, and Members ... discuss the Department of Justice,s,efforts to protect intellectual ...
... longer than previously assumed , WEDNESDAY, Nov. 7 (HealthDay ... according to a study that found the duration of ... That means many people may be getting booster shots ... say. , Based on the findings, it may be ...
... their risk for neurodevelopmental trouble, researchers say, , , WEDNESDAY, ... couldn,t live without their morning coffee, but caffeine may ... premature infants. , New research finds that high doses ... -- an average of 27 weeks gestation -- reduced ...
... NEWS, Va., Nov. 7 This past weekend ... Compact Gamma,Cameras" were presented at the Nuclear Science ... The goal of the laboratory study was to ... system in a configuration in which,the two imaging ...
Cached Medicine News:Health News:American Medical Association Clears Path for Adenoviral Conjunctivitis - 'Pink Eye' - Detector 2Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 2Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 3Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 4Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 5Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 6Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 7Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 8Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 9Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 10Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 11Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 12Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 13Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 14Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 15Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 16Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 17Health News:Written Statement of Kevin J. O'Connor, Chairman of the Department of Justice Task Force on Intellectual Property, at the Senate Judiciary Committee Hearing on Intellectual Property Enforcement 18Health News:Many Vaccine Booster Shots Unnecessary: Study 2Health News:Caffeine Therapy Boosts Preemies' Outcomes 2Health News:Caffeine Therapy Boosts Preemies' Outcomes 3Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 2Health News:Dilon Technologies Explores Improvements in Molecular Breast Imaging 3
... System has been designed so the surgeon ... soft tissue away from the operative surface. ... procedure without stay-sutures or assistance. This controlled ... freedom to do other tasks, which will ...
... a revolutionary new addition to the Hall® ... PowerPro Battery System is the first and ... on the market. It is a full-function ... the requirements of large bone, small bone, ...
... Plus is a truly flexible system offering ... range of applications, inlcuding orthopedics, abdominal surgery, ... and more. , ,By offering ... sizes, evolutive memory capacities and a wide ...
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
Medicine Products: